Grifols (NSDQ:GRFS) said today that it paid $51 million for a 49% stake in Access Biologicals, in a deal that includes an option to acquire the rest of the business.
That option, for the remaining 51% share in Vista, Calif.-based Access, goes live in 2022, Grifols said. The agreement also includes a provision to supply Access with non-human-use biologicals, the Spanish company said.
“The purpose of this acquisition is to enhance the activity of the Bio Supplies Division,” formerly the raw materials division, Grifols said in a regulatory filing.
Get the full story at our sister site, Drug Delivery Business News.
The post Grifols pays $51m for minority stake in Access Biologicals appeared first on MassDevice.